ReviewAnnual review of pathology2019
Pathology and Pathogenesis of Chagas Heart Disease.
Review in Annual review of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 136 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
136 citing papers in PubMed, 2 syntheses or guidelines pooled it, 241 citations in OpenAlex.
- Monotherapy and combination chemotherapy for Chagas disease treatment: a systematic review of clinical efficacy and safety based on randomized controlled trials.Parasitology · 2022Pooled it
- Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Pooled it
- Integrated Experimental and Computational Investigation of Azobenzenoid Derivatives Against Trypanosomatid: RNA Editing Ligase 1 as a Potential Molecular Target.Acta parasitologica · 2026Article
- Multiparticulate Drug Delivery Systems Preserve the Efficacy of Reduced-Dose Intermittent Benznidazole Therapy in Experimental Chagas Disease.Research square · 2026Article
- Article
- Multitarget Therapeutic Strategies for Chagas Disease: Natural Compounds, Antimicrobial Peptides, and Cell-Based Immunomodulation.Infectious disease reports · 2026Review
- RIG-I-Adjuvanted Immunogen Elicited T-Cell Immunity Controls Trypanosoma cruzi, Chagasic Cardiomyopathy, and Left Ventricular Dysfunction.JACC. Basic to translational science · 2026Article
- IL-33/ST2 Signaling Protects the Heart by Restraining Inflammation and Parasite Burden duringACS infectious diseases · 2026Article
- Protective immunity against Chagas disease induced by a superantigen-based chimeric DNA vaccine delivered by attenuatedFrontiers in immunology · 2026Article
- A Rapid Method for Purifying Intact Trypanosoma cruzi Amastigotes from Host Cells, In Vitro and In Vivo, for Downstream 'Omic Analysis.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Comparative 5' IsomiRome Analysis Uncovers Dysregulated 5' IsomiRs inComputational and structural biotechnology journal · 2026Article
- Article
- Evaluation of Apolipoprotein-A1 genetic polymorphisms as biomarkers for Chagas cardiomyopathy in patients from Córdoba, Argentina.Molecular biology reports · 2025Observational
- Intestinal immunopathological evaluation of mice reinfected with Trypanosoma cruzi Y strain.PLoS neglected tropical diseases · 2025Article
- Clinical Progression of Cardiac ChronicPathogens (Basel, Switzerland) · 2025Article
- Beyond cardiac embolism and cryptogenic stroke: unveiling the mechanisms of cerebrovascular events in Chagas disease.Lancet regional health. Americas · 2025Review
- Collaborative Synthesis for Neglected Diseases through the Open Synthesis Network: Structure-Activity Relationships of Arylaminopyrazoles as Chagas Disease Treatments.ACS infectious diseases · 2025Article
- New derivatives of 6-nitrocoumarin-3-thiosemicarbazone exhibit improved antiparasitic activity in the placenta againstAntimicrobial agents and chemotherapy · 2025Article
- Article
- Coinfection by multipleMicrobiology and molecular biology reviews : MMBR · 2025Review
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Chagas heart disease is an inflammatory cardiomyopathy that develops in approximately one-third of people infected with the protozoan parasite Trypanosoma cruzi. One way T. cruzi is transmitted to people is through contact with infected kissing bugs, which are found in much of the Western Hemisphere, including in vast areas of the United States. The epidemiology of T. cruzi and Chagas heart disease and the varied mechanisms leading to myocyte destruction, mononuclear cell infiltration, fibrosis, and edema in the heart have been extensively studied by hundreds of scientists for more than 100 years. Despite this wealth of knowledge, it is still impossible to predict what will happen in an individual infected with T. cruzi because of the tremendous variability in clonal parasite virulence and human susceptibility to infection and the lack of definitive molecular predictors of outcome from either side of the host-parasite equation. Further, while several distinct mechanisms of pathogenesis have been studied in isolation, it is certain that multiple coincident mechanisms combine to determine the ultimate outcome. For these reasons, Chagas disease is best considered a collection of related but distinct illnesses. This review highlights the pathology and pathogenesis of the most common adverse sequela of T. cruzi infection-Chagas heart disease-and concludes with a discussion of key unanswered questions and a view to the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.